CEO Talk In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with his company. He also offers advice to the next generation of Taiwanese pharmaceutical companies. To read the first part of…
Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…
Generics The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded products. What was the strategy behind the integration of Novopharm into Teva? Novopharm is one of the pioneers in the…
Clinical trials TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take, and explains the decision to market the drug first in China. Nemonoxacin will be the first-ever pharmaceutical developed in this…
Basic Research A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of biotech to drive the Taiwanese economy in the years to come, and Taiwan’s China connection. Participants: Hsing-Jien Kung, President, National…
Gene Health The President of Gene Health, a company specialized in genomics testing, talks about the current market situation for genomic testing, and building the business in the Chinese market, as well as the company’ relationship with Vita Genomics. What interested you in the genomics business, and what are your strategies for…
Economy “As Mexicans we must be prepared for a new stage of our country’s development”. These were the inspiring words of newly elected Mexican President Peña Nieto, who has promised to transform Mexico into a competitive global power. As the world’s thirteenth largest economy, there is no question that Mexico…
Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…
Department of Investment Services The General Director of the ‘Invest in Taiwan’ program discusses Taiwan’s competitiveness on a global and regional level, highlights the areas and industrial sectors where the country is looking to invest, and talks about the importance of further economic integration with its neighbours in order to realize its potential. Can…
investment In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and biotech companies over the last fifteen years, and goes in-depth into the company’s innovative pipeline, including UBI’s possible HIV cure.…
Inlicensing The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development ecosystem in Taiwan, and the acquire-develop-transfer model of doing business. Throughout our interviews in Taiwan, several industry stakeholders have expressed…
investment Cormac Callaghan, founder and managing director of Primecore, a portfolio and program management consultancy based in Dublin and Cambridge, Massachusetts, has managed large-scale change programs for the pharmaceutical industry for the better part of 30 years. He has seen his share of setbacks: between 2006 and 2008, Callaghan was the…
See our Cookie Privacy Policy Here
